

Mireia Casulleras

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3783952/publications.pdf>

Version: 2024-02-01

38
papers

7,447
citations

172457

29
h-index

315739

38
g-index

38
all docs

38
docs citations

38
times ranked

17488
citing authors

#	ARTICLE	IF	CITATIONS
1	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). <i>Autophagy</i> , 2016, 12, 1-222.	9.1	4,701
2	Resolvin D1 and Its Precursor Docosahexaenoic Acid Promote Resolution of Adipose Tissue Inflammation by Eliciting Macrophage Polarization toward an M2-Like Phenotype. <i>Journal of Immunology</i> , 2011, 187, 5408-5418.	0.8	360
3	Role for PPAR β in obesity-induced hepatic steatosis as determined by hepatocyte- and macrophage-specific conditional knockouts. <i>FASEB Journal</i> , 2011, 25, 2538-2550.	0.5	325
4	Inhibition of soluble epoxide hydrolase modulates inflammation and autophagy in obese adipose tissue and liver: Role for omega-3 epoxides. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 536-541.	7.1	185
5	Effects of Albumin Treatment on Systemic and Portal Hemodynamics and Systemic Inflammation in Patients With Decompensated Cirrhosis. <i>Gastroenterology</i> , 2019, 157, 149-162.	1.3	178
6	Molecular interplay between δ 5/ δ 6 desaturases and long-chain fatty acids in the pathogenesis of non-alcoholic steatohepatitis. <i>Gut</i> , 2014, 63, 344-355.	12.1	107
7	Prostaglandin E2 Exerts Multiple Regulatory Actions on Human Obese Adipose Tissue Remodeling, Inflammation, Adaptive Thermogenesis and Lipolysis. <i>PLoS ONE</i> , 2016, 11, e0153751.	2.5	98
8	Resolvin D1 primes the resolution process initiated by calorie restriction in obesity-induced steatohepatitis. <i>FASEB Journal</i> , 2014, 28, 836-848.	0.5	97
9	Cell-specific PPAR β deficiency establishes anti-inflammatory and anti-fibrogenic properties for this nuclear receptor in non-parenchymal liver cells. <i>Journal of Hepatology</i> , 2013, 59, 1045-1053.	3.7	91
10	Signaling and Immunoresolving Actions of Resolvin D1 in Inflamed Human Visceral Adipose Tissue. <i>Journal of Immunology</i> , 2016, 197, 3360-3370.	0.8	87
11	Orchestration of Tryptophan-Kynurenine Pathway, Acute Decompensation, and Acute-on-Chronic Liver Failure in Cirrhosis. <i>Hepatology</i> , 2019, 69, 1686-1701.	7.3	80
12	Pro-resolving mediators produced from EPA and DHA: Overview of the pathways involved and their mechanisms in metabolic syndrome and related liver diseases. <i>European Journal of Pharmacology</i> , 2016, 785, 133-143.	3.5	73
13	Coordinate Functional Regulation between Microsomal Prostaglandin E Synthase-1 (mPGES-1) and Peroxisome Proliferator-activated Receptor β (PPAR β) in the Conversion of White-to-brown Adipocytes. <i>Journal of Biological Chemistry</i> , 2013, 288, 28230-28242.	3.4	72
14	Frontline Science: Specialized proresolving lipid mediators inhibit the priming and activation of the macrophage NLRP3 inflammasome. <i>Journal of Leukocyte Biology</i> , 2018, 105, 25-36.	3.3	72
15	Oxidized Albumin Triggers a Cytokine Storm in Leukocytes Through P38 Mitogen-Activated Protein Kinase: Role in Systemic Inflammation in Decompensated Cirrhosis. <i>Hepatology</i> , 2018, 68, 1937-1952.	7.3	70
16	Resolution of inflammation in obesity-induced liver disease. <i>Frontiers in Immunology</i> , 2012, 3, 257.	4.8	67
17	Leukocytes, Systemic Inflammation and Immunopathology in Acute-on-Chronic Liver Failure. <i>Cells</i> , 2020, 9, 2632.	4.1	65
18	Role of bioactive lipid mediators in obese adipose tissue inflammation and endocrine dysfunction. <i>Molecular and Cellular Endocrinology</i> , 2016, 419, 44-59.	3.2	64

#	ARTICLE	IF	CITATIONS
19	Disruption of the 12/15-lipoxygenase gene (Alox15) protects hyperlipidemic mice from nonalcoholic fatty liver disease. <i>Hepatology</i> , 2010, 52, 1980-1991.	7.3	59
20	The specialized proresolving lipid mediator maresin 1 protects hepatocytes from lipotoxic and hypoxia-induced endoplasmic reticulum stress. <i>FASEB Journal</i> , 2017, 31, 5384-5398.	0.5	56
21	The soluble guanylate cyclase stimulator IWX1973 prevents inflammation and fibrosis in experimental nonalcoholic steatohepatitis. <i>British Journal of Pharmacology</i> , 2018, 175, 953-967.	5.4	53
22	Mitochondrial dysfunction governs immunometabolism in leukocytes of patients with acute-on-chronic liver failure. <i>Journal of Hepatology</i> , 2022, 76, 93-106.	3.7	51
23	Targeted lipidomics reveals extensive changes in circulating lipid mediators in patients with acutely decompensated cirrhosis. <i>Journal of Hepatology</i> , 2020, 73, 817-828.	3.7	48
24	Albumin internalizes and inhibits endosomal TLR signaling in leukocytes from patients with decompensated cirrhosis. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	47
25	Leukocytes from obese individuals exhibit an impaired SPM signature. <i>FASEB Journal</i> , 2019, 33, 7072-7083.	0.5	45
26	New insights into the role of macrophages in adipose tissue inflammation and fatty liver disease: modulation by endogenous omega-3 fatty acid-derived lipid mediators. <i>Frontiers in Immunology</i> , 2011, 2, 49.	4.8	40
27	Polymorphisms in the IL1 gene cluster influence systemic inflammation in patients at risk for acute-on-chronic liver failure. <i>Hepatology</i> , 2017, 65, 202-216.	7.3	39
28	Pro-resolving actions of SPM in adipose tissue biology. <i>Molecular Aspects of Medicine</i> , 2017, 58, 83-92.	6.4	33
29	Anti-Inflammatory and Proresolving Effects of the Omega-6 Polyunsaturated Fatty Acid Adrenic Acid. <i>Journal of Immunology</i> , 2020, 205, 2840-2849.	0.8	33
30	Stimulation of soluble guanylate cyclase exerts antiinflammatory actions in the liver through a VASP/NF- κ B/NLRP3 inflammasome circuit. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 28263-28274.	7.1	31
31	Untargeted lipidomics uncovers lipid signatures that distinguish severe from moderate forms of acutely decompensated cirrhosis. <i>Journal of Hepatology</i> , 2021, 75, 1116-1127.	3.7	31
32	Association of a variant in the gene encoding for ERV1/ChemR23 with reduced inflammation in visceral adipose tissue from morbidly obese individuals. <i>Scientific Reports</i> , 2017, 7, 15724.	3.3	27
33	Albumin protects the liver from tumor necrosis factor α -induced immunopathology. <i>FASEB Journal</i> , 2021, 35, e21365.	0.5	15
34	Proresolving lipid mediators and liver disease. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2021, 1866, 159023.	2.4	11
35	Reduced Plasma Extracellular Vesicle CD5L Content in Patients With Acute-On-Chronic Liver Failure: Interplay With Specialized Pro-Resolving Lipid Mediators. <i>Frontiers in Immunology</i> , 2022, 13, 842996.	4.8	11
36	Essential lipid autacoids rewire mitochondrial energy efficiency in metabolic dysfunction-associated fatty liver disease. <i>Hepatology</i> , 2023, 77, 1303-1318.	7.3	10

#	ARTICLE	IF	CITATIONS
37	Mitochondrial Dysfunction in Advanced Liver Disease: Emerging Concepts. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 772174.	3.5	9
38	Albumin Lipidomics Reveals Meaningful Compositional Changes in Advanced Cirrhosis and Its Potential to Promote Inflammation Resolution. <i>Hepatology Communications</i> , 2022, 6, 1443-1456.	4.3	6